

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-C

REPORT BY ISSUER OF SECURITIES QUOTED  
ON NASDAQ INTERDEALER SYSTEM

Filed pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934  
and Rule 13a-17 or 15d-17 thereunder

ENZON, INC.

(Exact name of issuer as specified in charter)

Delaware (State of Incorporation)	0-12957 (Commission File No.)	22-237286 (IRS Employer Identification No.)
---	----------------------------------	---

I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate any change (increase or decrease) of 5% or more of the number of shares outstanding:

1. TITLE OF SECURITY: Common Stock, par value \$.01
2. NUMBER OF SECURITIES OUTSTANDING BEFORE THE CHANGE:  
24,427,217
3. NUMBER OF SECURITIES OUTSTANDING AFTER THE CHANGE:  
26,328,874
4. EFFECTIVE DATE OF CHANGE: June 30, 1995
5. METHOD OF CHANGE: The shares of common stock (the "Common Stock"

or "Common Shares") were issued in connection with (a) the sale to Susquehanna Brokerage Services, Inc. ("Susquehanna") of an aggregate of 954,000 shares of Common Stock pursuant to a Third Amended and Restated Purchase Agreement dated as of June 24, 1994 and entered into by and between Enzon, Inc. (the "Company") and Susquehanna (the "Susquehanna Purchase Agreement"); (b) the sale in a private transaction of 847,489 shares of Common Stock pursuant to a Stock Purchase Agreement dated as of June 30, 1995 (the "Stock Purchase Agreement"); (c) the issuance to the Company's former landlord of 100,000 shares of Common Stock in connection with the settlement of a dispute; and (d) the merger (the "Merger") pursuant to a Merger Agreement (the "Merger Agreement") dated June 12, 1991 by and among the Company, Genex Corporation, a Delaware corporation

("Genex") and Enzon Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of the Company ("EAC") pursuant to which EAC was merged into Genex with Genex as the surviving corporation, at which time Genex changed its name to Enzon Labs Inc. ("Enzon Labs").

6. BRIEF DESCRIPTION OF TRANSACTIONS: Between August 5, 1994 and January 5, 1995, the Company issued an aggregate of 954,000 shares of Common Stock to Susquehanna for aggregate consideration of \$1,963,609. The offer and sale of the 954,000 shares through Susquehanna as underwriter were among the shares of Common Stock registered on the Company's Registration Statement on Form S-3 (File No. 33-80790) which also constituted a post-effective amendment to the Company's Registration Statement on Form S-3 (File No. 33-74272) declared effective by the Securities and Exchange Commission on July 18, 1994.

On June 30, 1995 the Company sold an aggregate of 847,489 shares of Common Stock in a private transaction for aggregate consideration of \$2,000,000. Such shares of Common Stock are restricted and certain registration rights were granted with respect thereto.

In April 1995 the Company issued 100,000 shares of restricted Common Stock to its former landlord in connection with the termination of a lease and settlement of a dispute with respect thereto.

In connection with the Merger, shares of Genex Capital Stock were converted into the right to receive shares of the Company's Common Stock through October 1994 and warrants to purchase shares of the Company's Common Stock at an exercise price of \$18 per share through October 1994. From May 26, 1994, the date of the last filing of this report, through June 30, 1995 a total of 168 shares of Common Stock have been issued upon exchange of shares of Genex Capital Stock.

Enzon, Inc.

Date: July 19, 1995

By: /S/ KENNETH ZUERBLIS  
Kenneth Zuerblis

Vice President, Finance and Chief  
Financial Officer  
(Principal Financial  
and Accounting Officer)